Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | REN | P00797 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 2/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18256528 | 0.91 | SYK (0.40) | CTSKCTSLCTSBCTSSMMP13 | |
| SCHEMBL18248075 | 0.91 | SYK (0.40) | CTSKCTSLCTSBCTSSMMP13 | |
| SCHEMBL21447947 | 0.90 | CTSK (0.46) | CTSKCTSLCTSBCTSSMMP13 | |
| SCHEMBL21447763 | 0.90 | CTSK (0.46) | CTSKCTSLCTSBCTSSMMP13 | |
| SCHEMBL19066731 | 0.90 | CTSK (0.46) | CTSKCTSLCTSBCTSSMMP13 | |
| SCHEMBL18256324 | 0.90 | CTSK (0.46) | CTSKCTSLCTSBCTSSMMP13 | |
| SCHEMBL18248083 | 0.90 | CTSK (0.46) | CTSKCTSLCTSBCTSSMMP13 | |
| SCHEMBL22502801 | 0.89 | CTSK (0.38) | CTSKCTSLCTSBCTSSMMP13 | |
| SCHEMBL23269885 | 0.88 | MMP13 (0.39) | CTSKCTSLCTSBCTSSMMP13 | |
| SCHEMBL18248147 | 0.88 | MMP13 (0.39) | CTSKCTSLCTSBCTSSMMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786575-B2 | Endoparasitic depsipeptides | ZOETIS SERVICES LLC (US) | 2023-10-17 | — | — | US | disclosed |
| US-20220211802-A1 | Endoparasitic Depsipeptides | ZOETIS SERVICES LLC | 2022-07-07 | — | — | US | disclosed |
| US-20200354408-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11786575-B2 | Endoparasitic depsipeptides | VIP, PREP, NGLY1 | CTSK 518/4885CTSL 75/4885CTSB 143/4885 |
| US-20220211802-A1 | Endoparasitic Depsipeptides | VIP, PREP, NGLY1 | CTSK 518/4885CTSL 75/4885CTSB 143/4885 |
| US-20200354408-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | CTSK 204/4885CTSL 86/4885CTSB 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.